Prognostic Value of miR-145 in HER2-Positive Locally Advanced or Metastatic Urothelial Carcinoma Treated with Disitamab Vedotin
{{output}}
Disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate, has shown promising activity in locally advanced or metastatic urothelial carcinoma (la/mUC), but clinically useful biomarkers remain lacking. In this retrospective single-center real-world stu... ...